It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.
Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.
CRISPR Therapeutics ( CRSP -5.91%) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. Now, its challenge is to build on its prior ...
Rotten tomatoes no more: growing sweeter tomatoes is possible by editing just two of the fruit’s genes. Deleting the genes ...
We recently compiled a list of the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2024. In this article, we are going to ...
A CRISPR-Cas9-based investigational therapy was linked with a drop in serum transthyretin (TTR) levels in patients with ...
Life Sciences Center (LSC) have discovered a unique way for cells to silence specific genes without cutting DNA. This ...
In a phase 2 trial, a gene therapy reduced angioedema attacks, which could significantly change the quality of life for ...